Search Results - "Naidoo, Jarushka"

Immune-related adverse events and the balancing act of immunotherapy by Conroy, Michael, Naidoo, Jarushka

“…The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and…”
Get full text

Cardiovascular complications of immune checkpoint inhibitors for cancer by Thuny, Franck, Naidoo, Jarushka, Neilan, Tomas G

“…Over the last decade or so, there has been a paradigm shift in the oncologic care of patients with a range of solid tumour and haematologic malignancies, away…”
Get full text

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer by Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

“…The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression…”
Get full text

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity by Cluxton, Christopher, Naidoo, Jarushka

“…Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained anti-tumour responses in a wide variety of malignancies. The…”
Get full text

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma by Chen, Linda, Douglass, Jacqueline, Kleinberg, Lawrence, Ye, Xiaobu, Marciscano, Ariel E., Forde, Patrick M., Brahmer, Julie, Lipson, Evan, Sharfman, William, Hammers, Hans, Naidoo, Jarushka, Bettegowda, Chetan, Lim, Michael, Redmond, Kristin J.

“…To characterize the effect of concurrent stereotactic radiosurgery–stereotactic radiation therapy (SRS-SRT) and immune checkpoint inhibitors on patient…”
Get full text

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers by Caushi, Justina X., Zhang, Jiajia, Ji, Zhicheng, Vaghasia, Ajay, Zhang, Boyang, Hsiue, Emily Han-Chung, Mog, Brian J., Hou, Wenpin, Justesen, Sune, Blosser, Richard, Tam, Ada, Anagnostou, Valsamo, Cottrell, Tricia R., Guo, Haidan, Chan, Hok Yee, Singh, Dipika, Thapa, Sampriti, Dykema, Arbor G., Burman, Poromendro, Choudhury, Begum, Aparicio, Luis, Cheung, Laurene S., Lanis, Mara, Belcaid, Zineb, El Asmar, Margueritta, Illei, Peter B., Wang, Rulin, Meyers, Jennifer, Schuebel, Kornel, Gupta, Anuj, Skaist, Alyza, Wheelan, Sarah, Naidoo, Jarushka, Marrone, Kristen A., Brock, Malcolm, Ha, Jinny, Bush, Errol L., Park, Bernard J., Bott, Matthew, Jones, David R., Reuss, Joshua E., Velculescu, Victor E., Chaft, Jamie E., Kinzler, Kenneth W., Zhou, Shibin, Vogelstein, Bert, Taube, Janis M., Hellmann, Matthew D., Brahmer, Julie R., Merghoub, Taha, Forde, Patrick M., Yegnasubramanian, Srinivasan, Ji, Hongkai, Pardoll, Drew M., Smith, Kellie N.

“…PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can…”
Get full text

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis by Abu-Sbeih, Hamzah, Ali, Faisal S, Naqash, Abdul Rafeh, Owen, Dwight H, Patel, Sandipkumar, Otterson, Gregory A, Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K, Wang, Yinghong

“…Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors…”
Get full text

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab by Cappelli, Laura C, Gutierrez, Anna Kristina, Baer, Alan N, Albayda, Jemima, Manno, Rebecca L, Haque, Uzma, Lipson, Evan J, Bleich, Karen B, Shah, Ami A, Naidoo, Jarushka, Brahmer, Julie R, Le, Dung, Bingham, 3rd, Clifton O

“…Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have…”
Get more information

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation by Braaten, Tawnie J, Brahmer, Julie R, Forde, Patrick M, Le, Dung, Lipson, Evan J, Naidoo, Jarushka, Schollenberger, Megan, Zheng, Lei, Bingham, Clifton O, Shah, Ami A, Cappelli, Laura C

“…We sought to investigate the long-term outcomes of patients who develop immune checkpoint inhibitor (ICI)-induced inflammatory arthritis (IA), to define…”
Get more information

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer by Anagnostou, Valsamo, Smith, Kellie N, Forde, Patrick M, Niknafs, Noushin, Bhattacharya, Rohit, White, James, Zhang, Theresa, Adleff, Vilmos, Phallen, Jillian, Wali, Neha, Hruban, Carolyn, Guthrie, Violeta B, Rodgers, Kristen, Naidoo, Jarushka, Kang, Hyunseok, Sharfman, William, Georgiades, Christos, Verde, Franco, Illei, Peter, Li, Qing Kay, Gabrielson, Edward, Brock, Malcolm V, Zahnow, Cynthia A, Baylin, Stephen B, Scharpf, Robert B, Brahmer, Julie R, Karchin, Rachel, Pardoll, Drew M, Velculescu, Victor E

“…Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have…”
Get more information

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events by Brahmer, Julie R, Abu-Sbeih, Hamzah, Ascierto, Paolo Antonio, Brufsky, Jill, Cappelli, Laura C, Cortazar, Frank B, Gerber, David E, Hamad, Lamya, Hansen, Eric, Johnson, Douglas B, Lacouture, Mario E, Masters, Gregory A, Naidoo, Jarushka, Nanni, Michele, Perales, Miguel-Angel, Puzanov, Igor, Santomasso, Bianca D, Shanbhag, Satish P, Sharma, Rajeev, Skondra, Dimitra, Sosman, Jeffrey A, Turner, Michelle, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes…”
Get full text

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets by Rekhtman, Natasha, Pietanza, Maria C, Hellmann, Matthew D, Naidoo, Jarushka, Arora, Arshi, Won, Helen, Halpenny, Darragh F, Wang, Hangjun, Tian, Shaozhou K, Litvak, Anya M, Paik, Paul K, Drilon, Alexander E, Socci, Nicholas, Poirier, John T, Shen, Ronglai, Berger, Michael F, Moreira, Andre L, Travis, William D, Rudin, Charles M, Ladanyi, Marc

“…Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive neoplasm, whose biologic relationship to small cell lung carcinoma (SCLC) versus…”
Get full text

Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond by Reuss, Joshua E., Suresh, Karthik, Naidoo, Jarushka

“…Purpose of Review Checkpoint inhibitor pneumonitis (CIP) is a toxicity of immune checkpoint blockade (ICB) that can be highly morbid and at times fatal. Here,…”
Get full text

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib by Naidoo, Jarushka, Sima, Camelia S., Rodriguez, Katherine, Busby, Natalie, Nafa, Khedoudja, Ladanyi, Marc, Riely, Gregory J., Kris, Mark G., Arcila, Maria E., Yu, Helena A.

“…BACKGROUND Epidermal growth factor receptor (EGFR) exon 20 insertions (exon20ins) represent approximately 10% of EGFR‐mutant lung adenocarcinomas, and are…”
Get full text

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement by Sears, Catherine R, Peikert, Tobias, Possick, Jennifer D, Naidoo, Jarushka, Nishino, Mizuki, Patel, Sandip P, Camus, Philippe, Gaga, Mina, Garon, Edward B, Gould, Michael K, Limper, Andrew H, Montgrain, Philippe R, Travis, William D, Rivera, M Patricia

“…Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening…”
Get full text

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen by Cappelli, Laura C., Brahmer, Julie R., Forde, Patrick M., Le, Dung T., Lipson, Evan J., Naidoo, Jarushka, Zheng, Lei, Bingham, Clifton O., Shah, Ami A.

“…Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a…”
Get full text

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer by Al-Rajabi, Taiseer, Naidoo, Jarushka, Zhang, Jun

Get full text

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy by Suresh, Karthik, Psoter, Kevin J, Voong, Khinh Ranh, Shankar, Bairavi, Forde, Patrick M, Ettinger, David S, Marrone, Kristen A, Kelly, Ronan J, Hann, Christine L, Levy, Benjamin, Feliciano, Josephine L, Brahmer, Julie R, Feller-Kopman, David, Lerner, Andrew D, Lee, Hans, Yarmus, Lonny, Hales, Russell K, D'Alessio, Franco, Danoff, Sonye K, Naidoo, Jarushka

“…With increasing use of immune checkpoint inhibitors (ICIs) for advanced NSCLC, there is increasing recognition of immune-related adverse events associated with…”
Get more information

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer by Phallen, Jillian, Leal, Alessandro, Woodward, Brian D, Forde, Patrick M, Naidoo, Jarushka, Marrone, Kristen A, Brahmer, Julie R, Fiksel, Jacob, Medina, Jamie E, Cristiano, Stephen, Palsgrove, Doreen N, Gocke, Christopher D, Bruhm, Daniel C, Keshavarzian, Parissa, Adleff, Vilmos, Weihe, Elizabeth, Anagnostou, Valsamo, Scharpf, Robert B, Velculescu, Victor E, Husain, Hatim

“…With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have…”
Get full text

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors by Shaikh, Fyza Y, White, James R, Gills, Joell J, Hakozaki, Taiki, Richard, Corentin, Routy, Bertrand, Okuma, Yusuke, Usyk, Mykhaylo, Pandey, Abhishek, Weber, Jeffrey S, Ahn, Jiyoung, Lipson, Evan J, Naidoo, Jarushka, Pardoll, Drew M, Sears, Cynthia L

“…While immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer by producing durable antitumor responses, only 10%-30% of treated patients…”
Get full text